Jain Global LLC Purchases 139,594 Shares of Abbott Laboratories $ABT

Jain Global LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 71.7% in the third quarter, HoldingsChannel.com reports. The firm owned 334,180 shares of the healthcare product maker’s stock after purchasing an additional 139,594 shares during the period. Abbott Laboratories comprises 0.2% of Jain Global LLC’s investment portfolio, making the stock its 24th largest position. Jain Global LLC’s holdings in Abbott Laboratories were worth $44,760,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Abbott Laboratories by 1.8% in the 2nd quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares during the period. State Street Corp increased its stake in shares of Abbott Laboratories by 0.9% during the second quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after buying an additional 689,517 shares during the period. Capital International Investors raised its holdings in shares of Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after acquiring an additional 1,478,076 shares in the last quarter. Norges Bank purchased a new stake in Abbott Laboratories in the second quarter worth $3,026,180,000. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Abbott Laboratories by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after acquiring an additional 821,325 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on ABT shares. Royal Bank Of Canada decreased their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Weiss Ratings cut shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Leerink Partners lowered their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. The Goldman Sachs Group cut their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Finally, Daiwa Securities Group reduced their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Abbott Laboratories Stock Down 0.1%

Shares of Abbott Laboratories stock opened at $107.99 on Monday. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $139.06. The firm has a market cap of $187.66 billion, a price-to-earnings ratio of 29.03, a PEG ratio of 1.72 and a beta of 0.74. The company has a 50-day moving average of $114.58 and a 200 day moving average of $123.80. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the previous year, the firm posted $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Insider Buying and Selling

In other news, SVP Eric Shroff sold 709 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president owned 104,291 shares of the company’s stock, valued at $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,055 shares of company stock worth $353,097 over the last three months. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.